Brief: Lantern Pharma Announces First Patient Dosed In Phase 2 Study, Harmonic, For Lp-300 In Never Smokers With Advanced Non-Small Cell Lung Cancer
28/03/2023 13:22
March 28 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN THE PHASE
2
STUDY, HARMONIC™, FOR LP-300 IN NEVER SMOKERS WITH ADVANCED
NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nBw1lTS2Qa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview